Denver District Office
6 th Ave & Kipling St, Bldg 20 DFC
P.O. Box 25087
Denver, CO 80225 

 
 

 

November 30, 2017
 
WARNING LETTER
  
Via UPS Overnight
 
Ref: # HAFW4(DEN)-18-02-WL
 
David A. Brown, Owner
TruVision Health, LLC
12162 South Business Park Drive
Suite 114
Draper, UT 84790
 
Dear Mr. Brown:
 
On May 15, 22-25, 30-31, 2017, the U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 12162 South Business Park Drive, Suite 114, Draper, Utah. The inspection revealed serious violations of FDA’s Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(g)(1)] in that the products have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Further, a review of the product labels collected during the inspection, and a review of your website at https://truvisionhealth.com/, identified serious violations of the Act and applicable regulations.  You can find copies of the Act and pertinent regulations through links on FDA’s homepage at www.fda.gov.
 
Unapproved New Drugs and Misbranded Drugs
 
FDA reviewed your website at the internet address https://truvisionhealth.com/ in November 2017 and has determined that you take orders there for the products truWeight & Energy™ Gen 2, Ubiquinol, Omega 3, Pycnogenol®, reNU, and truElevate™. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.  As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. 
 
Examples of some of the claims that provide evidence that your products are intended for use as drugs include the following:
 
truWeight & Energy™ Gen 2
Ubiquinol
Omega 3
reNU
truElevate™
Pycnogenol®
Your products are not generally recognized as safe and effective for the above-referenced uses and therefore, the products are “new drugs” under section 201(p)(1) of the Act [21 U.S.C. § 321(p)(1)]. New drugs may not be legally marketed in the United States without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d) and 355(a)].  FDA approves a new drug based on scientific data submitted by a drug sponsor to demonstrate the drug is safe and effective.
 
A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s).  “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
 
Your products truWeight & Energy™ Gen 2, Pycnogenol®, and truElevate™ are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, truWeight & Energy™ Gen 2, Pycnogenol®, and truElevate™ fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)].  The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].
 
Adulterated Dietary Supplements
 
Your dietary supplement products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because the products have been held under conditions that do not meet the Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (CGMP) regulation, Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111). Additionally, even if your truWeight & Energy™ Gen 2, Ubiquinol, Omega 3, reNU, and truElevate™ products did not have therapeutic claims which make them unapproved new drugs and/or misbranded drugs, these products would be adulterated dietary supplements within the meaning of section 402(g)(1) of the Act [21 U.S.C. §342(g)(1)] because the products have been held under conditions that do not meet the Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (CGMP) regulation, Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111). 
 
Specifically, your quality control unit failed to approve for release, or reject, any packaged and labeled dietary supplement (including a repackaged or relabeled dietary supplement), as required by 21 CFR 111.127(h). You also failed to make and keep written documentation, at the time of performance, that quality control personnel performed the required quality control review, as required by 21 CFR 111.140(b)(2). At the time of the inspection, you had no quality control procedures in place, and this deficiency was noted in the Form FDA 483 issued to you at the close of the inspection. In your response dated July 14, 2017, you provided copies of your new Standard Operating Procedures (SOPs) for quality control. While your new SOPs provide, some information pertaining to the quality control procedures we understand that you intend to implement, the information provided with your response fails to demonstrate that you are conducting the required quality control procedures for approving for release, or rejecting, your packaged and labeled dietary supplement for distribution. The adequacy of your corrective actions will be evaluated during the next inspection.
 
As a distributor that contracts with a manufacturer to manufacture, package, and label dietary supplements on your behalf that your firm releases for distribution under your firm’s name, your firm has an obligation to know what and how manufacturing, packaging, and/or labeling activities are performed so that you can make decisions related to whether your dietary supplement products conform to established specifications and whether to approve and release the products for distribution [72 Fed. Reg. 34752, 34790 (Jun. 25, 2007)]. Although a firm may contract out certain dietary supplement manufacturing, packaging, and/or labeling operations, it cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce (or causes to be placed into commerce) is not adulterated for failure to comply with dietary supplement CGMP requirements (see United States v. Dotterweich. In particular, the Act prohibits a person from introducing or delivering for introduction, or causing the delivery or introduction, into interstate commerce a dietary supplement that is adulterated under section 402(g) for failure to comply with dietary supplement CGMP requirements [see 21 U.S.C. §§ 342(g) and 331(a)]. Thus, a firm that contracts out some or all its operations must establish a system of production and process controls to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (21 CFR 111.55). The quality control personnel must also ensure that the manufacturing, packaging, labeling, and holding operations ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (21 CFR 111.105)., 320 U.S. 277, 284 (1943) (explaining that an offense can be committed under the Act by anyone who has “a responsible share in the furtherance of the transaction which the statute outlaws”); United States v. Park, 421 U.S. 658, 672 (1975) (holding that criminal liability under the Act does not turn on awareness of wrongdoing, and that “agents vested with the responsibility, and power commensurate with that responsibility, to devise whatever measures are necessary to ensure compliance with the Act” can be held accountable for violations of the Act)
 
We also note that in your response letter dated July 14, 2017, you provided finished product specifications for truWeight & Energy GEN2 and truFix dietary supplements. Conducting quality control to ensure that these specifications are met is insufficient to ensure the quality of the dietary supplement. Specifically, “identity” of a dietary supplement refers to the dietary supplement’s consistency with the master manufacturing record and/or that it is the same as described in the master manufacturing record [see 72 FR at 34803]. Your identity specification for physical property describes the appearance and physical attributes of the dietary supplement; however, these attributes alone do not adequately ensure the dietary supplements’ consistency with the master manufacturing record to ensure the quality of the dietary supplement. Therefore, such specifications would not provide an appropriate basis upon which your quality control personnel could rely on for approval for release of any packaged and labeled dietary supplement for distribution [21 CFR 111.127(h)].
 
Misbranded Dietary Supplements
 
Based on labeling collected during the inspection of your firm, we note that several of your products are misbranded under section 403 of the Act and FDA’s labeling regulations, Title 21, Code of Federal Regulations, Part 101 (21 CFR 101), as follows: 
 
1.    Your truWeight & Energy™ Gen 2, truSlumber™, and reNU™ products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343 (q)(1)(A)], because the serving size declared on the labels are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. For example, your truWeight & Energy™ Gen 2 and reNU™ product label directions of use suggest the consumer takes one or two capsules, but the serving size lists one capsule.
 
2.    Your Complete™ Men’s Multivitamin, Complete™ Women’s Multivitamin, Omega 3, truSlumber™, Ubiquinol, reNU™, and truWeight & Energy™ Gen 2 products are misbranded within the meaning of sections 403(q)(1)(B) [21 U.S.C. §343(q)(1)B] and 403(q)(5)(F) of the Act [21 U.S.C. §§ 343(q)(5)(F)] because the labels fail to declare the number of servings per container under the serving size on the left hand side of the nutrition label or fails to include this information as part of the net quantity of contents declaration in accordance with 21 CFR 101.36(b)(1)(ii).
 
3.    Your reNU™, Omega 3, truSlumber™ and truWeight & Energy™ Gen 2 products are misbranded within the meaning of section 403(q)(5)(F) of the Act [U.S.C. § 343(q)(5)(F)] because the labels fail to bear nutrition labeling in the form of a “Supplement Facts” label that is not in accordance with 21 CFR 101.36.  For example,
4.    Your truWeight & Energy™ Gen 2 and truSlumber™ products are misbranded within the meaning of section 403(r)(6)(C) of the Act [21 U.S.C. §343(r)(6)(C)] because each product label makes structure function claims but fails to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).
 
5.    Your truSlumber™ product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product is fabricated from two or more ingredients, but the label fails to bear the common or usual names of each ingredient used in the product, as required by 21 CFR 101.4.  For example, the product label lists “cyracos” and “Gaba Calm”. The ingredients of your product must be listed by their common or usual names, as required by 21 CFR 101.4(a) and (h). We suggest that you review the requirements for designation of ingredients in 21 CFR 101.4 and the general principles for common or usual names in 21 CFR 102.5(a) and (d) to help you determine how these ingredients should be declared on the label of your product.
 
6.    Your truWeight & Energy™ Gen 2 product is misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 343(s)(2)(B)] because the label fails to identify the products using the term “dietary supplement” in accordance with 21 CFR 101.3(g). The label includes a Supplements Facts label, which is evidence of your intent to market the product as a Dietary Supplement, but the product’s statement of identity does not comply with 21 CFR 101.3(g), which requires that a dietary supplement be identified by the term “dietary supplement” as part of the product’s statement of identity, except the word “dietary” may be deleted and replaced by the name of the dietary ingredient in the product.
 
7.    Your Complete™ Women’s Multivitamin product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). We note the term “Horsetail Extract (Aerial Parts)” does not comply with this requirement.
 
8.    Your truWeight & Energy™ Gen 2 product is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement. “Domestic address or domestic phone number” means a complete address or phone number.
 
(b)(3)(A)
 
We have determined that your facility is (b)(3)(A). During the inspection of your facility located at 12162 South Business Park Drive, Suite 114, Draper, Utah from May 15, 22-25, and 30-31, 2017, you were (b)(3)(A).
 
As a responsible official of a facility that manufactures/processes, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are following the law.
 
(b)(3)(A)
 
This letter is not an all-inclusive list of the violations that may exist at your facility or in connection with your products. It also does not indicate that FDA has conducted an all-inclusive review of all the products you manufacture and/or distribute. It is your responsibility to ensure the products you manufacture and/or distribute are following all applicable statutes and regulations, including the Act and applicable FDA regulations. You should take prompt action to correct all the violations noted in this letter and establish and implement procedures that will prevent the recurrence of these violations and the occurrence of other violations. Failure to implement lasting corrective actions may result in FDA taking regulatory action, including, without limitation, seizure or injunction.
 
In addition, we note the following:
Please respond to this office in writing within fifteen (15) working days from your receipt of this letter. In your response, identify the steps you have taken or will take to correct the above-noted violations and prevent similar ones.  In your response, please include the timeframe in which the corrections will be completed and provide any documentation that will effectively assist us in evaluating whether the corrective actions have been made and the adequacy of such corrective actions.  If you are unable to complete the corrective actions within fifteen (15) working days, identify the reason for the delay and the time within which you will complete the corrections.
 
Section 743 of the Act [21 U.S.C. 379j-31] authorizes FDA to assess and collect fees to cover FDA’s costs for certain activities, including reinspection-related costs.  A reinspection is one or more inspections conducted after an inspection that identified noncompliance materially related to a food safety requirement of the Act, specifically to determine whether compliance has been achieved. Reinspection-related costs mean all expenses, including administrative expenses incurred in connection with FDA’s arranging, conducting, and evaluating the results of the reinspection and assessing and collecting the reinspection fees [21 U.S.C. 379j-31(a)(2)(B)]. For a domestic facility, FDA will assess and collect fees for reinspection-related costs from the responsible party for the domestic facility. The inspection noted in this letter identified noncompliance materially related to a food safety requirement of the Act. Accordingly, FDA may assess fees to cover any reinspection-related costs.
 
Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer, P.O. Box 25087, 6th Ave & Kipling St, Bldg 20 DFC, Denver, Colorado, 80225-0087. You may reach Ms. Potter at (303) 236-3094 or via email at hanna.potter@fda.hhs.gov if you have any questions about this matter.
 
Sincerely,
/S/ 
LaTonya M. Mitchell
Denver District Director
Program Division Director
Office of Human and Animal Food Operations
Division IV West  
 

This page was posted on April 30, 2019.

Links to Recommended Companies

  • PharmacyChecker.com: Compare drug prices and save money at verified online pharmacies.
  • ConsumerLab.com: Evaluates the quality of dietary supplement and herbal products.
  • Amazon.com: Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.